Fatal agranulocytosis associated with Metamizole treatment in a 16-year-old girl

Article Sidebar

PDF HTML
Submitted: September 20 2019
Published: Oct 2, 2019
DOI: 10.29328/journal.acr.1001019
Keywords:
Agranulocytosis, Novalgin

Main Article Content

Packo Dieu-le-veut Saint-Cyr Sylvestre*
Department of Clinical Hematology, Yopougon Teaching Hospital, Abidjan, Côte d’Ivoire
Nanho Danho Clotaire
Department of Hepato-Gastroenterology, “Amitié sino-Centrafricaine” Teaching Hospital, Central African Republic
N’dhatz Comoe Emeraude
Department of Clinical Hematology, Yopougon Teaching Hospital, Abidjan, Côte d’Ivoire
Boidy Kouakou
Department of Clinical Hematology, Yopougon Teaching Hospital, Abidjan, Côte d’Ivoire
Camengo Police Serge Magloire
Department of Hepato-Gastroenterology, “Amitié sino-Centrafricaine” Teaching Hospital, Central African Republic
Diakité Mamady
Department of Clinical Hematology, DONKA Teaching Hospital, Guinea Conakry
Mbelesso Pascal
Department of Neurology, “Amitié sino-Centrafricaine” Teaching Hospital, Central African Republic
Koffi Kouassi Gustave
Department of Clinical Hematology, Yopougon Teaching Hospital, Abidjan, Côte d’Ivoire

Abstract

Agranulocytosis is one of the common reasons of consultation in hematology. It’s life-threatening because of an infection risk. The metamizole is a drug, known for its potential rare danger of inducing a severe agranulocytosis. However, it remains widely used because of its beneficial effect analgesic and antipyretic. We report in this study, a case of a girl who was 16 years old, referred for severe agranulocytosis, and appeared two weeks after treatment with Novalgin. The clinico-biological symptoms were dominated by Streptococcal septicemia with an infectious pulmonary and digestive focus. The blood cell count confirmed a severe agranulocytosis with total disappearance of neutrophils. Despite broad-spectrum antibiotic therapy and stimulation with hematopoietic growth factor, the clinical evolution was fatal in the short term. What motivates us to add this case to those of the literature in order to remind practitioners about the danger of this drug, and to promote has doubled of vigilance during use.

Article Details

Saint-Cyr Sylvestre, P. D.- le- veut, Clotaire, N. D., Emeraude, N. C., Kouakou, B., Serge Magloire, C. P., Mamady, D., … Gustave, K. K. (2019). Fatal agranulocytosis associated with Metamizole treatment in a 16-year-old girl. Archives of Case Reports, 3(1), 035–037. https://doi.org/10.29328/journal.acr.1001019
Case Reports

Copyright (c) 2019 Saint-Cyr Sylvestre PD, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Fillet, Georges. Agranulocytose médicamenteuse. Méd et hyg. 1984; 42: 2533-2541.

Bassetti S. Absence of evidence is not evidence of absence. In Forum Médical Suisse 2017; 17: 1059-1060.

Garcia S, Canionero M, Lopes G. Dipyrone-induced granulocytopenia: a case for awareness. Pharmacotherapy. 2006; 26:440-442. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16503727

Haschke M, Liechti ME. Métamizole: bénéfices et risques par rapport au paracétamol et aux AINS. Forum Med Suisse. 2017; 17:1067–1073.

Gupta BMD. Rapport sur un cas mortel d'agranulocytose. Ind Med Gaz. 1936; 71: 589-590. PubMed PMID: 29013107; PubMed Central PMCID: PMC5170691.

Rollason V, Desmeules JA. Use of metamizole in children and the risk of agranulocytosis. Is the benefit worth the risk?. Eur J Anaesthesiol. 2015; 32:837-848. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26509242

Benjamin J, Biederman J. Agranulocytic leukopenia induced by a drug related to aminopyrine. Journ Am Med. 1936; 107:493-494.

Fieler M, Eich C, Becke K, Badelt G, Leimkühler K, et al. Metamizole for postoperative pain therapy in 1177 children. A prospective, multicentre, observational, post authorisation safety study. Eur J Anaesthesiol 2015; 32:839-843. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26086280

Altman D, Bland J. Absence of evidence is not evidence of absence. Br Med Journ 1995; 311: 485.

Huber M, Andersohn F, Sarganas G, Bronder E, Klimpel A, et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case–Control Surveillance Study. Eur J Clin Pharmacol 2015; 71:219-227. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25378038

Salama A, Schtz B, Kiefel V, Breithaupt H, Mueller‐Eckhardt C. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989; 72:127-132. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2788011

Paitel JF, Stockemer V, Dorvaux V, Witz F, Guerci A, et al. Agranulocytoses aiguës médicamenteuses. Etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies. Rev méd int. 1995; 16:495-499.